Category: Pharmaceuticals

Pharmaceuticals

Interim Analysis: Sustained Wakefulness with Alixorexton in Narcolepsy

New data from a long-term extension study demonstrates sustained improvements in wakefulness, cognition, and fatigue for adults with narcolepsy type 1 and type 2.

Pharmaceuticals

Narcolepsy Treatments Are Advancing. Can Access?

Race, age, and other factors are linked to disparities in care for people with narcolepsy.

Positive Interim Analysis Advances Avecho Phase III Insomnia Trial for CBD Capsule
Melatonin Can Be a Safe and Effective Sleep Aid for All Ages—But Product Inconsistencies and Improper Dosing Lead to Real Harms
Semaglutide Associated With Lower Incidence of OSA in Post Hoc Analysis
Health Canada Approves Zepbound for OSA in Adults With Obesity
Eli Lilly Completes Acquisition of Centessa Pharmaceuticals to Advance Narcolepsy Treatments
Lilly’s Investigational Triple Agonist Retatrutide Reduces OSA Severity in Phase 3 Trial
Apnimed Appoints New CEO as Investigational OSA Therapy Nears FDA Decision

Pharmaceuticals

New Pivotal Study Data Released for Takeda’s Oveporexton

New phase 3 data indicate that Takeda’s investigational orexin agonist, oveporexton, significantly improves daily functioning, cognition, and nighttime sleep in patients with narcolepsy type 1.

Prescription Drugs

Harmony Biosciences’ Four Key Pillars to Drive Value Creation

Harmony Biosciences reported a 17% year-over-year growth for WAKIX in the first quarter of 2026 and detailed four strategic priorities focused on long-term growth.

Over-the-Counter Treatments

Saline Nasal Spray Shows Efficacy in Treating Pediatric Sleep-Disordered Breathing

A new Australian study finds that a simple saline nasal spray can resolve symptoms of obstructive sleep-disordered breathing in children, potentially reducing the need for surgery and specialist care.

Emerging Compounds

Incannex Healthcare Commences DReAMzz Clinical Study for IHL-42X in OSA

The crossover dose optimization study aims to refine the dosing profile of the oral therapy and strengthen the design of the planned phase III development program.